Centaur Pharma’s Clinical Research Division, LifeSan Clinical Research Receives Zero 483 Observations From Back-to-Back US FDA Inspections


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
LifeSan Clinical Research, the clinical research division of Centaur Pharmaceuticals was audited by the US FDA and was concluded with zero 483 observations which signifies compliance and conformance to applicable GCP regulations. LifeSan has successfully faced 6 inspections from US FDA; 2 inspections from MHRA/ EMA and 1 inspection from MCC, South Africa, in its twelve years of existence.

Mr. S.D Sawant, Managing Director, Centaur Pharmaceuticals said, “The zero 483 observations to our clinical research division, LifeSan Clinical Research is yet another feather in our cap. We are happy with this significant development not only for Centaur but also for the Indian pharmaceutical industry. In addition to US FDA accreditation, the said facility also conforms to MHRA (UK), TGA (Australia), Health Canada, MCC (South Africa) and WHO-GMP standards.”

It undertakes bioavailability/ bioequivalence studies, which are mandatory for generic drug approval process and phase II/III clinical trials. Since inception, LifeSan has submitted many studies to regulatory agencies of US FDA, EMA, MCC South Africa and TGA, Australia as well as CDSCO, the Indian Drug Regulatory Authority, including successful conduct of phase II and III clinical trial of a new chemical entity [NCE].

Earlier in May 2019, Centaur Pharmaceuticals oral solid dosage facility in Pune had received no action indicated (NAI) compliance status with zero 483 observations from the US FDA. In addition to US FDA accreditation, the Pune facility also conforms to MHRA (UK), TGA (Australia), Health Canada, MCC (South Africa) and WHO-GMP standards.
 
Centaur Pharmaceuticals is a US$ 100 million Indian pharmaceutical company with exports to 110 countries. Centaur has presence across the pharmaceutical value chain with proficiency in API, formulations, clinical research and contract manufacturing. Centaur is India’s largest and the world’s third largest manufacturer of psychotropic API with state of the art facility conforming to US FDA, EUGMP/ANSM (France), TGA, PMDA (Japan), KFDA (Korea), ANVISA (Brazil), COFEPRIS (Mexico) and WHO-GMP standards. On the domestic front, Centaur ranks among India’s top 35 firms by prescriptions. Centaur’s flagship brand Sinarest is a leader in the anticold market since 1996 and has won the AWACS brand of the year award for marketing excellence consecutively for the past 5 years. Centaur ranks among India’s top 5 companies in ophthalmologicals, with the highest growth trajectory.

Tags : #LifeSan # # #Clinical #Research # #US #FDA

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

No health without rights, says Shobha Shukla SDG-3 Lead Discussant at UN meetJuly 15, 2025
30 Minutes To Freedom, Robotic Surgery Ends 89-YO’s Swallowing NightmareJuly 15, 2025
Himalaya Wellness Champions Bhringaraja in New Anti-Hair Fall Campaign with a Tale of FriendshipJuly 15, 2025
ViiV Healthcare and Medicines Patent Pool extends voluntary licensing agreement to enable access to long-acting injectable HIV treatment July 15, 2025
Reforming global financial architecture is critical for gender equality and right to healthJuly 14, 2025
Francesco Arezzo takes office as president of Rotary InternationalJuly 14, 2025
CBM India Highlights Inclusive Eye Health at VISION 2020: The Right to Sight – INDIA 19th Annual ConferenceJuly 14, 2025
Crompton Introduces Ameo Fresh Nutri Blender, Reinforcing Its Promise of ‘Healthy Choices Made Easy’July 14, 2025
NMC Notifies Medical Institutions (Qualifications of Faculty) Regulations, 2025 to Expand Medical Education Capacity and Strengthen Faculty Availability July 14, 2025
India’s Roads, India’s Pain: Healing Beyond the HospitalJuly 14, 2025
When Weathers Go Deadly: Role Of Climate Change In Stimulating The Proliferation Of Disease-carrying VectorsJuly 14, 2025
India’s Hidden Health Emergency: Climate Pressures on WellbeingJuly 14, 2025
The Silent Urgency: Why Geriatric Health Homes Can’t Wait AnymoreJuly 14, 2025
Rewiring the Brain: How Neuroscience Apps Are Changing Stroke RecoveryJuly 14, 2025
Healing Happens at Home: How Community Care Breaks the Cycle of Repeat Hospital TripsJuly 14, 2025
The Future Is Hands-On: How AR Is Quietly Reshaping Physical TherapyJuly 14, 2025
Flying Lifelines: Why Medical Drones are Changing Supply Chains in SilenceJuly 14, 2025
The Silent Hunger Are Well Fed Indian Teens Actually MalnourishedJuly 14, 2025
Richest 1% people have enough new wealth to end annual poverty 22 times overJuly 11, 2025
Fermenta Signs Strategic MoU with NIFTEM-T to Strengthen India’s Food Fortification LandscapeJuly 11, 2025